{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:42:21Z","timestamp":1791567741074,"version":"4.3.4"},"reference-count":27,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acquired hemophilia A (AHA) is an autoimmune disorder characterized by the formation of autoantibodies that neutralize the function of coagulation factor VIII. Immunosuppressive therapy (IST) with glucocorticoids, cyclophosphamide, rituximab, or combinations thereof is the standard of care to suppress autoantibody formation and induce remission of AHA. About 80% of patients achieve remission over the course of a few weeks to several months. However, patients with AHA are often elderly and frail and have adverse events from IST. Therefore, guidelines suggest an individualized approach using caution in elderly and frail patients. Prophylaxis with emicizumab may reduce the need for early and aggressive IST in the future.<\/jats:p>","DOI":"10.1182\/hematology.2023000461","type":"journal-article","created":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:07:50Z","timestamp":1702048070000},"page":"19-23","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Immunotherapy of acquired hemophilia A"],"prefix":"10.1182","volume":"2023","author":[{"given":"Andreas","family":"Tiede","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,12,8]]},"reference":[{"issue":"7","key":"2023120815052769200_hem2023000461C1","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am J Hematol"},{"issue":"7","key":"2023120815052769200_hem2023000461C2","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2023120815052769200_hem2023000461C3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2011.04309.x","article-title":"Management of acquired haemophilia A","volume":"9","author":"Collins","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2023120815052769200_hem2023000461C4","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2016-11-751347","article-title":"Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A","volume":"130","author":"Kahle","year":"2017","journal-title":"Blood"},{"issue":"19","key":"2023120815052769200_hem2023000461C5","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1182\/blood-2015-09-672774","article-title":"Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"127","author":"Tiede","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2023120815052769200_hem2023000461C6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/bloodadvances.2022008071","article-title":"Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01\/2010 study","volume":"7","author":"Oleshko","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023120815052769200_hem2023000461C7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1055\/s-0038-1650169","article-title":"A survey of 215 non-hemophilic patients with inhibitors to factor VIII","volume":"45","author":"Green","year":"1981","journal-title":"Thromb Haemost"},{"issue":"5A","key":"2023120815052769200_hem2023000461C8","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1016\/S0002-9343(91)80142-9","article-title":"Cytotoxic suppression of acquired factor VIII:C inhibitors","volume":"91","author":"Green","year":"1991","journal-title":"Am J Med"},{"issue":"1","key":"2023120815052769200_hem2023000461C9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2141.2003.04162.x","article-title":"Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors","volume":"121","author":"Delgado","year":"2003","journal-title":"Br J Haematol"},{"issue":"5","key":"2023120815052769200_hem2023000461C10","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2023120815052769200_hem2023000461C11","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"issue":"7","key":"2023120815052769200_hem2023000461C12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2023120815052769200_hem2023000461C13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.26009","article-title":"Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study","volume":"96","author":"Schep","year":"2021","journal-title":"Am J Hematol"},{"issue":"19","key":"2023120815052769200_hem2023000461C14","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2023120815052769200_hem2023000461C15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/archinte.1987.00370060073014","article-title":"Acquired hemophilia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy","volume":"147","author":"Lottenberg","year":"1987","journal-title":"Arch Intern Med"},{"key":"2023120815052769200_hem2023000461C16","unstructured":"Levesque\n              H.\n            \n          \n          Outcome of acquired haemophilia with steroid combined with cyclophosphamide versus steroid combined with rituximab (CREHA study). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01808911. Accessed October7, 2023."},{"issue":"1","key":"2023120815052769200_hem2023000461C17","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1111\/hae.13658","article-title":"Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A","volume":"25","author":"Obaji","year":"2019","journal-title":"Haemophilia"},{"issue":"3","key":"2023120815052769200_hem2023000461C18","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023120815052769200_hem2023000461C19","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00277-020-04150-y","article-title":"Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study","volume":"99","author":"Dobbelstein","year":"2020","journal-title":"Ann Hematol"},{"issue":"18","key":"2023120815052769200_hem2023000461C20","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2022016873","article-title":"Combined immunosuppression for acquired hemophilia A: CyDRi is a highly effective low-toxicity regimen","volume":"140","author":"Simon","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023120815052769200_hem2023000461C21","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/S0049-3848(12)70019-1","article-title":"Acquired hemophilia in malignancy","volume":"129","author":"Reeves","year":"2012","journal-title":"Thromb Res"},{"issue":"1","key":"2023120815052769200_hem2023000461C22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.13355","article-title":"Acquired haemophilia in cancer: a systematic and critical literature review","volume":"24","author":"Napolitano","year":"2018","journal-title":"Haemophilia"},{"issue":"3","key":"2023120815052769200_hem2023000461C23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023120815052769200_hem2023000461C24","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2023120815052769200_hem2023000461C25","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/jth.15208","article-title":"Should emicizumab be used in patients with acquired hemophilia A?","volume":"19","author":"Tiede","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2023120815052769200_hem2023000461C26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2023120815052769200_hem2023000461C27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/19\/2175516\/19tiede.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2023\/1\/19\/2175516\/19tiede.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T15:08:07Z","timestamp":1702048087000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2023\/1\/19\/506407\/Immunotherapy-of-acquired-hemophilia-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,8]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12,8]]},"published-print":{"date-parts":[[2023,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2023000461","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,8]]},"published":{"date-parts":[[2023,12,8]]}}}